Horizon Pharma announces patent allowance from USPTO Horizon Pharma announced that Skyepharma has received a Notice of Allowance from the United States Patent and Trademark Office, or USPTO, for U.S. Patent Application 13/713,528 entitled "Delayed-Release Tablet with Defined Core Geometry" that covers the Company's U.S. approved product RAYOS. This Notice of Allowance concludes the substantive examination of the patent application and will result in the issuance of a U.S. patent after administrative processes are completed. The U.S. patent scheduled to issue from this application will expire in 2024. After issuance, Horizon plans to list the U.S. patent in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, or Orange Book. This will be the fifth U.S. patent to be listed in the Orange Book for RAYOS.